The litigation targets alleged violations of the Securities Exchange Act of 1934, specifically centering on the company’s public statements regarding its product, neffy. According to the complaint, ARS Pharmaceuticals purportedly misled the market by downplaying risks associated with the timeline of CVS Caremark’s formulary addition. Plaintiffs argue the company recklessly disregarded potential shifts in insurance coverage, which ultimately impacted the drug’s commercial trajectory and caused financial harm to investors once the realities of the situation surfaced.

While the class has not yet been formally certified, legal representatives Brian Schall and David Schwartz are inviting affected parties to discuss their rights. Participation in the lawsuit does not mandate an appointment as a lead plaintiff, and shareholders who choose not to act remain absent class members. Interested investors can reach the firm at their Los Angeles office or via their website to review the filing details before the upcoming October cut-off.